News

Pegasys users may now access resources to help with reimbursement issues through Genentech

For more information about the Genentech Patient Foundation and to learn if a patient receiving a Genentech product (such as Pegasys) is eligible to receive support, please visit www.gene.com/patients/patient-foundation or call the Patient Resource Center at 877-GENENTECH.

Patient Advocates Take Aim at Progression in Myeloproliferative Neoplasms

Through a one-year pilot grant, the MPN Research Foundation (MPNRF) will provide funding to Dr. Ann Mullally and Dana-Farber Cancer Institute's Center for Prevention of Progression (CPOP) to study the genomic basis for MPN disease progression

Imago BioSciences Granted Fast Track Designation for IMG-7289 in Myelofibrosis

Imago BioSciences announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the development of IMG-7289 (bomedemstat) for the treatment of myelofibrosis.

Blood Cancer Awareness Month 2019

September provides the MPN community a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia, and myelofibrosis by celebrating nationally recognized Blood Cancer Awareness Month.

A method for detecting mutations and measuring gene-expression levels in the same cell has enabled an investigation into the effects of mutations in a specific gene on the emergence of a form of blood cancer..

Targeting the Aurora Kinase A Inhibition has potential benefit for patients with myelofibrosis.

In an article published by Targeted Oncology, Dr. Srdan Verstovsek, MD, Ph., discussed with a group of physicians the considerations he makes with the diagnosis and management of patients with myeloproliferative neoplasms (MPNs).

Mark Your Calendars - October 1 is Rare Cancer Day!

The National Organization for Rare Disorders (NORD) has announced a day devoted to raising awareness about rare cancers. Spearheaded by the NORD Rare Cancer Coalition, which is comprised of 24 rare cancer-specific Member Organizations.

Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm

Researchers recently published an article, "Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper," resulting from a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs in the management of thrombotic risk and thrombotic events associated with myeloproliferative neoplasms (MPNs).

Patient Power Interviews Dr. Ruben Mesa about Fedratinib Approval

BREAKING NEWS: The FDA has approved fedratinib as a new treatment option for myelofibrosis patients.

MPNRF Quoted in Cure Today Magazine

In an article published by CURE Today, MPN Research Foundation's Executive Director, Michelle Woehrle sat down to discuss the FDA's approval of new Myelofibrosis drug Inrebic (fedratinib), the first approved drug for the disease in nearly a decade.

Breaking: Inrebic (Fedratinib) approved for Myelofibrosis! This becomes the first FDA approved drug for an MPN in nearly a decade

It is an oral kinase inhibitor with activity against wild type and mutationally activated Janus Associated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3).

ASH Awards the 2019 William Dameshek Prize

The American Society of Hematology presented Emmanuelle Passegué, Ph.D., of Columbia University Irving Medical Center in New York City with the 2019 William Dameshek Prize for her outstanding contribution to the field of hematology.

CPI-0610 Demonstrates Activity in MF Patients After Ruxolitinib Failure

A researcher at Mt. Sinai in this video discusses observations from their clinical trial with the drug CPI-0610.

The MPN Familial Study

We know that myeloproliferative neoplasms may occasionally run in families, but what we don't know is why. The Fleischman Lab, headed by Dr. Angela Fleischman, MD. PhD. in Irvine, CA is seeking to answer that question.